内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NKTR 内克塔治疗

盘后交易 10-07 16:32:54 EDT

40.26

+0.35

+0.88%

盘后40.26

+0.000.00%

16:15 EDT

最高40.35	最低38.45	成交量144.54万
今开39.22	昨收39.91	日振幅4.77%
总市值13.75亿	流通市值13.51亿	总股本3,414万
成交额5,715万	换手率4.31%	流通股本3,355万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"内克塔治疗","latestPrice":40.26,"timestamp":1791403200000,"preClose":39.91,"halted":0,"volume":1445449,"hourTrading":{"tag":"盘后","latestPrice":40.26,"preClose":40.26,"latestTime":"16:15 EDT","volume":19080,"amount":768086.5788,"timestamp":1791404100192,"change":0,"changeRate":0,"amplitude":0.006138},"delay":0,"changeRate":0.008769731896767764,"floatShares":33545280,"shares":34142994,"eps":-6.468026,"marketStatus":"盘后交易","change":0.35,"latestTime":"10-07 16:32:54 EDT","open":39.22,"high":40.35,"low":38.445,"amount":57148573,"amplitude":0.047732,"askPrice":40.48,"askSize":6,"bidPrice":38.38,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.468026,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791417600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":39.91,"preHourTrading":{"tag":"盘前","latestPrice":39.25,"preClose":39.91,"latestTime":"09:29 EDT","volume":6102,"amount":239336.463852,"timestamp":1791379799999,"change":-0.66,"changeRate":-0.016537,"amplitude":0.042962},"postHourTrading":{"tag":"盘后","latestPrice":40.26,"preClose":40.26,"latestTime":"16:15 EDT","volume":19080,"amount":768086.5788,"timestamp":1791404100192,"change":0,"changeRate":0,"amplitude":0.006138},"volumeRatio":0.502184,"optionData":{"bulkOrders":[{"symbol":"NKTR","call":true,"expireDate":1863493200000,"strike":"70.0","timestamp":1791381819675,"price":11.5,"volume":1016,"amount":1168400,"type":"-"}]},"impliedVol":0.7732,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/NKTR/tweets","defaultTab":"tweets","newsList":[{"id":"1101597430","title":"异动解读｜内克塔治疗盘中下跌19.63%，报48.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101597430","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101597430?lang=zh_cn&edition=full","pubTime":"2026-10-02 02:39","pubTimestamp":1790879982,"startTime":"0","endTime":"0","summary":"10月1日，内克塔治疗盘中下跌19.63%，报48.66美元/股，成交额2.06亿美元。内克塔治疗所在的制药行业中，个股普遍承压，其中礼来跌0.77%，强生跌2.0%，默沙东跌1.03%，Liquidia Technologies跌11.63%，辉瑞跌1.21%。内克塔治疗是一家临床阶段研究型生物制药公司，专注于免疫治疗领域创新药物的发现和开发，致力于创造新的免疫调节剂以达到预期治疗效果。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670068442","title":"内克塔治疗（NKTR）盘前涨5% 诉礼来案胜诉 陪审团裁定赔偿9000万美元及利息","url":"https://stock-news.laohu8.com/highlight/detail?id=2670068442","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670068442?lang=zh_cn&edition=full","pubTime":"2026-09-25 19:34","pubTimestamp":1790336099,"startTime":"0","endTime":"0","summary":"金吾财讯 | 内克塔治疗（NKTR）盘前涨5.04%，报62.373美元。内克塔治疗公布，美国陪审团裁定礼来（LLY）在双方rezpegaldesleukin合作项目纠纷中，违反善意与公平交易默示契约，判决礼来向内克塔治疗支付9000万美元赔偿金并计付利息。本次陪审团裁决仍需经过庭审后续程序，最终判决结果存在被上诉的可能性。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/ZWJkNDM0ZDIxZGI0MmM2OTU5ZmFmYmIzNDdlN2ZlMTM1NjQzNTM3NDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWJkNDM0ZDIxZGI0MmM2OTU5ZmFmYmIzNDdlN2ZlMTM1NjQzNTM3NDg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306492","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","SG9999014914.USD","SG9999014906.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU2089283258.USD","LU2168564149.EUR","LU1551013342.USD","LU2360106947.USD","ILDR","IE0004445239.USD","LU1145028129.USD","BK4588","LU1061106388.HKD","LU0823434740.USD","TRUH","LU2361044949.HKD","LU0320765992.SGD","BK4585","CURE","LU2462591350.SGD","SG9999018865.SGD","LU2471134879.HKD","IE00BK4W5L77.USD","LU1720051017.SGD","BK4581","PJP","LU0689472784.USD","LU0456855351.SGD","LU2756315664.SGD","LU2746668461.USD","LU0094547139.USD","LU2028103732.USD","LU0471298694.HKD","LU1035775433.USD","LU2213496289.HKD","LLYZ","LU1868837136.USD","LU1868837300.USD","LU0234572021.USD","LU1989771016.USD","AGNG","LU2089984988.USD","LU0289739699.SGD","LU0640476718.USD","SG9999015952.SGD","LU2468319806.SGD","LU0471298777.SGD","LU2491050154.USD","LU2552382215.SGD","PPH","LU0061475181.USD","LU1804176565.USD","BK4533","LU2750360997.AUD","IE00BKPKM429.USD","LU2168564495.EUR","LLY","LU2896262040.SGD","IE00BJJMRY28.SGD","IE00BJT1NW94.SGD","SG9999001176.USD","LU2357305700.SGD","NKTR","LU0820562030.AUD","IE00BJJMRX11.SGD","GB00BDT5M118.USD","IE00B1XK9C88.USD","LU0158827948.USD","LU1979441026.SGD","LU2112291526.USD","LU1691799644.USD","LU2462157665.USD","LU1069344957.HKD","LU0708995401.HKD","RXL","LU0345770993.USD","LU1323610961.USD","SG9999015978.USD","SGXZ99366536.SGD","LU1280957306.USD","LU2168564065.EUR","LU0114720955.EUR","FTXH","LU2168563687.JPY","LU0820561909.HKD","IE00B4JS1V06.HKD","LU1712237335.SGD","LU2361044865.SGD","LU2023251221.USD","IE0009355771.USD","LU2361045086.USD","SGXZ51526630.SGD","LU1267930730.SGD","BK4007","LLII","LU0203202063.USD","LU1023059063.AUD","LU1064131342.USD","LU1093756168.USD","IE0005OL40V9.USD","LU1551013425.SGD","VHT","LU0079474960.USD","LU2271345857.HKD","LU2111349929.HKD","LU0345770308.USD","LU2471134796.USD","IE00BFTCPJ56.SGD","LU2106854487.HKD","SG9999015945.SGD","LU0174119429.USD","LU2324357040.USD","LU0353189680.USD","LU1623119135.USD","SG9999018857.SGD","TMED","CANC","LU1868836591.USD","LU2602419157.SGD","BK4534","LU0158827781.USD","LU2087625088.SGD","LU2756315318.SGD","SG9999014898.SGD","SGXZ81514606.USD","LU2063271972.USD","XLV","LU0122379950.USD","LU0198837287.USD","IE00BFSS7M15.SGD","IE00B1BXHZ80.USD","LU0353189763.USD","LU0385154629.USD","LU1988902786.USD","LU2108987350.USD","LU2417539215.USD","LU0943347566.SGD","LU1366192091.USD","LU2236285917.USD","LU0820561818.USD","LU0266013472.USD","LU0823434583.USD","SG9999015986.USD","LU1232071149.USD","LU0683600562.USD","LU0889565916.HKD","MEDI","SG9999001176.SGD","BK4516","IE00BFSS8Q28.SGD","LU0058720904.USD","IE0004445015.USD","LU2750360641.GBP","MHIP","LU0882574055.USD","LU1814569148.SGD","LU1974910355.USD","LU0672654240.SGD","LU2237443465.HKD","LU2265009873.SGD","ELIS","LU0238689110.USD","WDNA","LU0466842654.USD","SG9999014880.SGD","JDOC","IE00BN29S564.USD","LU1868836914.USD","IE00BWXC8680.SGD","LU1127390331.HKD","SG9999013999.USD","ELIL","LU0210536198.USD","LU0354030511.USD","LU2471134952.CNY","IE00BK4W5M84.HKD","OZEM","LU2552382132.HKD","LU0882574139.USD","LU2471134523.USD","IE0001KFT4U8.USD","LU2264538146.SGD","LU2456880835.USD","LU1093756325.SGD","IE00B7KXQ091.USD","LU0109394709.USD","LU0320765059.SGD","LU1548497426.USD","LU0787776722.HKD","LU2237443622.USD","LU0256863902.USD","LU1629891620.HKD","IYH","LU2023250504.SGD","LU0964807845.USD","LU0109391861.USD","LU0096364046.USD","LLYX","LU0786609619.USD","LU2461242641.AUD","IE00B775H168.HKD","SG9999017495.SGD","IHE","LU2211815571.USD","IE0002141913.USD","LU2491049909.HKD","LU2491050071.SGD","SGXZ31699556.SGD","LU1720051108.HKD","IXJ","LU0225283273.USD","LU2237443549.SGD","SGXZ57979304.SGD","LU0354030438.USD","LU2023250330.USD","BK4599","LU1983299246.USD","LU0823416689.USD","LU2237438978.USD","MEDX","LU2168564222.USD","LU0106261372.USD","LU2552382058.USD","IE00BJLML261.HKD","LU0203201768.USD","LU0006306889.USD","LU1868836757.USD","LU2089284900.SGD","IE00BKDWB100.SGD","LU2746668974.SGD","LU1057294990.SGD","LU0316494557.USD","GDOC","LU2237443382.USD","IE00B4R5TH58.HKD","LU0133085943.USD","HRTS","LU0323591593.USD","THNR","LU1917777945.USD","LU0097036916.USD","LU2237443895.HKD","LU2237443978.SGD","FHLC","LU1291159041.SGD","LU0417517546.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160123473","title":"内克塔治疗宣布自2026年9月8日起进入静默期，直至Rezolve-Aa二期B阶段研究数据公布——源自SEC申报文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1160123473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160123473?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:14","pubTimestamp":1788898450,"startTime":"0","endTime":"0","summary":"内克塔治疗近日通过美国证券交易委员会的申报文件披露，公司计划自2026年9月8日起步入一段静默期。这一特殊阶段将持续运作，直至备受关注的Rezolve-Aa二期B阶段临床试验数据正式对外揭晓。从具体时间节点来看，9月8日这一天成为了分水岭，此后内克塔治疗将限制对外发表可能影响市场预期的评论或数据。业界分析人士指出，Rezolve-Aa研究的结果对于内克塔治疗而言意义重大，可能直接影响其后续研发管线布局及市场估值走向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165480159","title":"内克塔治疗宣布Rezolve-Ad研究达标：Rezpegaldesleukin 24 μg/kg每两周方案全面实现主要及关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1165480159","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165480159?lang=zh_cn&edition=full","pubTime":"2026-08-25 20:31","pubTimestamp":1787661073,"startTime":"0","endTime":"0","summary":"内克塔治疗公司传来重磅消息——其Rezolve-Ad临床研究取得了令人瞩目的成果。该研究针对rezpegaldesleukin 24 μg/kg每两周一次的给药方案，现已达成所有主要终点和关键次要终点。Rezolve-Ad研究的全面成功，不仅验证了rezpegaldesleukin的药理活性，更为后续开发奠定了坚实基础。随着这些积极数据的公布，内克塔治疗在免疫学领域的布局再添重要砝码。rezpegaldesleukin作为备受瞩目的在研药物，其每两周一次24 μg/kg的给药方案若能最终获批，有望为相关疾病患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123088382","title":"财报前瞻｜内克塔治疗本季度营收预计小幅下滑，看空观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1123088382","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123088382?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:59","pubTimestamp":1785981549,"startTime":"0","endTime":"0","summary":"内克塔治疗将于2026年08月13日发布财报，市场关注收入承压与费用控制对利润端的影响。市场一致预期显示，内克塔治疗本季度营收预计为1,042.46万美元，同比下降3.91%；调整后每股收益预计为-1.99美元，同比变动34.61%；息税前利润预计为-5,373.57万美元，同比下降39.35%。本季度市场预计营收1,042.46万美元，较上年同期小幅下滑，说明现有版税来源未显著扩张。依据近半年公开报道的分析师及机构评论，对内克塔治疗的最新季度取向整体偏谨慎，看空观点占比较高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜内克塔治疗本季度营收预计小幅下滑，看空观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119586580","title":"内克塔治疗：三期关键顶线数据预计2028年中出炉，生物制品许可申请目标锁定2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1119586580","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119586580?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:01","pubTimestamp":1784631697,"startTime":"0","endTime":"0","summary":"内克塔治疗公司宣布，其三期临床试验的初步关键顶线数据预计将于2028年中期获得。该公司已将相关产品的生物制品许可申请目标时间定在2029年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158852357","title":"内克塔治疗启动Zenith AD三期项目，评估新型调节性T细胞生物制剂Rezpegaldesleukin用于中重度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1158852357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158852357?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:01","pubTimestamp":1784631693,"startTime":"0","endTime":"0","summary":"内克塔治疗公司宣布，正式启动其名为“Zenith AD”的三期临床项目。该项目旨在评估其新型调节性T细胞生物制剂Rezpegaldesleukin，用于治疗中重度特应性皮炎患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191612017","title":"内克塔治疗拟通过股权分配协议发行至多1.5亿美元普通股 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1191612017","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191612017?lang=zh_cn&edition=full","pubTime":"2026-05-09 05:13","pubTimestamp":1778274791,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，内克塔治疗公司计划通过一项股权分配协议，向市场发行价值最高达1.5亿美元的普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193135314","title":"财报前瞻｜内克塔治疗本季度营收预计同比-30.74%，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1193135314","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193135314?lang=zh_cn&edition=full","pubTime":"2026-05-01 00:39","pubTimestamp":1777567157,"startTime":"0","endTime":"0","summary":"内克塔治疗将于2026年05月07日（盘后）发布财报，市场关注营收回落与临床推进下的费用与亏损趋势。当前一致预期显示，本季度内克塔治疗营收预计为1,063.62万美元，同比-30.74%；每股收益预计为-1.60，同比+35.29%；息税前利润预计为-3,956.11万美元，同比-32.68%；未检索到本季度毛利率和净利润的明确预测，相关指标暂不展示。市场预计本季度营收为1,063.62万美元，同比-30.74%，主要受非现金版税摊销节奏影响，收入基数环比上季明显下行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜内克塔治疗本季度营收预计同比-30.74%，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132475222","title":"内克塔治疗计划将净收益用于研发、临床开发及一般公司用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1132475222","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132475222?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:03","pubTimestamp":1776715391,"startTime":"0","endTime":"0","summary":"生物技术公司内克塔治疗（Nektar Therapeutics）宣布，其获得的净收益将主要投入研发活动、临床项目推进以及满足一般企业运营需求。此举旨在加速公司管线药物的开发进程，并为日常运营提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724318","title":"美股异动 | 斑秃治疗药物试验取得预期结果 内克塔治疗(NKTR.US)暴涨超24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628724318?lang=zh_cn&edition=full","pubTime":"2026-04-20 23:01","pubTimestamp":1776697275,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，内克塔治疗早盘暴涨超24%，年内累涨150%。在发布斑秃研究延长期治疗结果后，Oppenheimer公司重申了对内克塔治疗股票的“跑赢大盘”评级和140.00美元的目标价，认为24g/kg剂量组在第52周的综合SALT≤20应答率约为28%，符合其最佳预期范围。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132398328","title":"内克塔治疗股价盘前飙升17.8% 斑秃疗法扩展研究展现潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1132398328","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132398328?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:30","pubTimestamp":1776688214,"startTime":"0","endTime":"0","summary":"内克塔治疗公司股价在盘前交易中大幅上涨17.8%，此前其针对斑秃的治疗方案在扩展研究中显示出积极前景。这项延续性研究结果增强了投资者对该疗法商业化潜力的信心，推动公司市值显著提升。\n临床数据显示，该疗法在长期用药情况下仍能维持疗效，为受斑秃困扰的患者提供了新的治疗希望。市场观察人士指出，这一突破性进展可能重塑自身免疫性疾病治疗领域的竞争格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144614206","title":"内克塔治疗：94%患者完成治疗延长期 实现临床显著毛发增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1144614206","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144614206?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:34","pubTimestamp":1776684867,"startTime":"0","endTime":"0","summary":"生物技术公司内克塔治疗公布的最新临床数据显示，在接受治疗延长期方案的患者群体中，高达94%的参与者顺利完成全程治疗，并展现出具有临床意义的毛发增长效果。这一突破性进展为脱发治疗领域注入了新的希望。\n研究结果表明，绝大多数患者在延长治疗周期后不仅保持了治疗依从性，更在毛发再生指标上获得实质性改善。该数据进一步验证了治疗方案在长期应用中的有效性与安全性，为后续商业化推广提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154617428","title":"Rezolve-AA研究16周双盲延长期52周顶线结果：Rezpegaldesleukin在重度至极重度斑秃患者中展现疗效持续深化","url":"https://stock-news.laohu8.com/highlight/detail?id=1154617428","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154617428?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:32","pubTimestamp":1776684765,"startTime":"0","endTime":"0","summary":"Rezolve-AA临床研究最新公布的52周顶线数据显示，在完成16周双盲治疗延长期后，Rezpegaldesleukin对重度至极重度斑秃患者展现出持续深化的治疗效果。这项关键性延伸研究进一步验证了该疗法在长期用药过程中的应答强化趋势，为斑秃治疗领域提供了新的临床证据。\n斑秃作为一种自身免疫性疾病，其重度患者群体长期面临治疗选择有限的困境。此次公布的延长期结果不仅证实了治疗效果的持续性，更显示出随着用药时间的延长，患者临床应答程度呈现逐步加深的积极态势。该发现对推进斑秃治疗方案的优化具有重要意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109702235","title":"内克塔治疗将于2026年4月20日召开电话会议 讨论Rezpegaldesleukin治疗斑秃的Rezolve-AA二期B研究16周延长期52周顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1109702235","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109702235?lang=zh_cn&edition=full","pubTime":"2026-04-20 00:01","pubTimestamp":1776614476,"startTime":"0","endTime":"0","summary":"内克塔治疗宣布，公司计划于2026年4月20日举行一场电话会议，重点讨论其药物Rezpegaldesleukin用于治疗斑秃的Rezolve-AA二期B期临床研究的最新数据。\n此次会议将深入解读该研究16周延长治疗期结束后获得的52周顶线结果。这些关键数据将有助于评估该疗法在斑秃患者中的长期疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518278576","title":"内克塔治疗盘中异动 股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518278576?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613473,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，内克塔治疗股票出现异动，股价急速下跌5.25%。截至发稿，该股报0.832美元/股，成交量8612股，换手率0.00%，振幅0.00%。机构评级方面，在所有9家参与评级的机构中，44%的券商给予买入建议，44%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.59%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021311398a29c97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021311398a29c97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517416256","title":"内克塔治疗盘中异动 股价大涨5.06%报0.901美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517416256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517416256?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276885,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时01分，内克塔治疗股票出现波动，股价快速上涨5.06%。截至发稿，该股报0.901美元/股，成交量26.0674万股，换手率0.14%，振幅9.76%。机构评级方面，在所有8家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.47%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000126989ec59a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000126989ec59a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517602474","title":"内克塔治疗盘中异动 股价大涨5.45%报0.846美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517602474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517602474?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:59","pubTimestamp":1741111142,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日01时59分，内克塔治疗股票出现异动，股价急速上涨5.45%。截至发稿，该股报0.846美元/股，成交量79.266万股，换手率0.43%，振幅8.90%。机构评级方面，在所有8家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.35%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015903abe828f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015903abe828f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516744543","title":"内克塔治疗盘中异动 快速拉升5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516744543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516744543?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:53","pubTimestamp":1740761596,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时53分，内克塔治疗股票出现异动，股价大幅上涨5.15%。截至发稿，该股报0.837美元/股，成交量36.4781万股，换手率0.20%，振幅7.33%。机构评级方面，在所有8家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.47%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301005316abe10c02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301005316abe10c02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385612","title":"内克塔治疗盘中异动 急速上涨6.36%报0.830美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385612","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385612?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666680,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，内克塔治疗股票出现波动，股价快速拉升6.36%。截至发稿，该股报0.830美元/股，成交量2.2083万股，换手率0.01%，振幅7.64%。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.06%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223120abdf6e75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223120abdf6e75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.3263},{"period":"1month","weight":-0.4621},{"period":"3month","weight":-0.4449},{"period":"6month","weight":-0.4873},{"period":"1year","weight":-0.3341},{"period":"ytd","weight":-0.0561}],"compareEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":0.0116},{"period":"3month","weight":0.0452},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1425}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nektar Therapeutics于1990年在加州成立，并于1998年重新在特拉华州注册。该公司是一家临床阶段、研究型药物发现生物制药公司，专注于发现和开发免疫治疗领域的创新药物。在这个不断增长的领域内，该公司致力于创造新的免疫调节剂，选择性地诱导、放大、减弱或阻止免疫反应，以达到预期的治疗效果。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.34375,"avgChangeRate":-0.004399},{"month":6,"riseRate":0.424242,"avgChangeRate":0.026471},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.018591},{"month":8,"riseRate":0.484848,"avgChangeRate":0.043831},{"month":9,"riseRate":0.484848,"avgChangeRate":0.036592},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.03291},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"内克塔治疗","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"内克塔治疗,NKTR,内克塔治疗股票,内克塔治疗股票老虎,内克塔治疗股票老虎国际,内克塔治疗行情,内克塔治疗股票行情,内克塔治疗股价,内克塔治疗股市,内克塔治疗股票价格,内克塔治疗股票交易,内克塔治疗股票购买,内克塔治疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}